Around 50% of FTD patients do not have TDP-43 misregulation while 97% of ALS patients have TDP-43 aggregation (54,55), suggesting that only TDP-43-positive patients would benefit from RV inhibition. The gene discussed is TARDBP; the disease is frontotemporal dementia.